Updated September 2026 (2): adds the reported vote margins, which show the committee was closely divided on every substance - Emideltide was declined by a single vote. The outcome is unchanged; the margins qualify how much weight it can bear.

Updated September 2026: makes the emideltide/DSIP relationship explicit up front, since "emideltide" is now the name readers encounter first in regulatory coverage while "DSIP" is the name used in the marketing they saw earlier. No facts have changed since August; the July 2026 recommendation remains nonbinding and no rulemaking has begun.

Updated August 2026: corrects the framing of the July 2026 vote - this was a nonbinding advisory committee recommendation, not an FDA rejection, and nothing about DSIP's legal status changed.

Of the seven peptides the FDA's Pharmacy Compounding Advisory Committee (PCAC) reviewed on 23–24 July 2026, DSIP was the story that got least attention and arguably says the most. Six substances cleared the committee; DSIP was the single one it declined to recommend. For anyone weighing sleep peptides, that's a useful signal about where the evidence sits - but it is a signal, not a ruling, and the distinction matters more than the headlines allowed.

Emideltide and DSIP are the same thing

Start here, because a lot of confusion downstream comes from not starting here.

Emideltide is the name the substance carries on the FDA's compounding docket. Delta sleep-inducing peptide (DSIP) is the name it carries in the research literature and, more to the point, in the marketing. They refer to the same nonapeptide. There is no "emideltide versus DSIP" comparison to make, no scenario in which one is approved and the other isn't, and no meaningful sense in which one is the "pharmaceutical version" of the other.

This matters practically for two reasons. First, if you searched one name and found nothing, that is a search artefact and not a finding - everything written about DSIP applies to emideltide and vice versa. Second, anything marketed as though the two are distinct products, or as though the docket name confers some regulatory standing the older name lacks, is misrepresenting the substance. The docket name is a naming convention, not a status.

What actually happened: the committee declined to recommend Emideltide (DSIP)

On the second day of the meeting (24 July 2026), the committee considered the cognitive, longevity and sleep candidates. Semax and Epitalon were recommended for the 503A Bulk Drug Substances List; Emideltide was not. It was the only unfavourable vote of the two-day session. The full breakdown of all seven is in the FDA vote recap.

Be precise about what this was. The PCAC is an advisory committee. Its votes are nonbinding recommendations to the FDA about eligibility for a compounding bulks list - nothing more. A committee declining to recommend a substance is not an FDA rejection of that substance, and it is not a safety finding, a ban, or a scheduling action. The FDA alone decides what goes on the 503A list, and it does so through a sequence that has barely begun: advisory vote → FDA docket review → publication of a proposed rule → public comment period → final rule. As of today, none of that has happened for any of the seven substances, favourable vote or otherwise, and rulemaking of this kind typically runs well over a year. DSIP's legal status is exactly what it was on 22 July 2026.

It is also worth stating what a 503A Category 1 listing would and would not mean, since this is the question the docket is actually about. It would make a substance eligible to be compounded by a 503A pharmacy. It would not be an FDA approval, would not establish efficacy for any indication, and would not represent a finding that the substance works. Eligibility to be compounded and evidence that something helps are entirely separate questions, and the July vote spoke only to the first.

Why the evidence base is the likely driver

The most defensible reading of the outcome is the simplest one: the evidence. DSIP was isolated decades ago in connection with delta-wave (deep) sleep in early animal research - which is where its name and its entire marketing pitch come from. But its human evidence is limited, dated and mixed, its mechanism has never been firmly established, and it does not behave like a reliable sleep agent in the way the name implies. Set against the (already contested) preclinical cases for the six substances that were recommended, DSIP's record was the thinnest in the room.

That said, we should not over-read a single vote. Committee members are not required to give reasons, published deliberations are limited, and a vote count is not a published rationale. What can be said without speculation is that DSIP's human evidence base is weak on its own merits, independent of anything a committee did in July.

How close the votes actually were

The margins matter here, and they cut against confident readings in both directions. Three tallies have since been independently confirmed: BPC-157 and KPV each 8–6 with one abstention, and MOTS-c 7–5 with two abstentions. The Emideltide outcome is also confirmed: declined 6-7 with one abstention (six in favour, seven against). Reported but not yet confirmed against the official minutes: Semax 8–5 with one abstention and Epitalon 7–4 with one abstention. For TB-500, the honest statement is that it was recommended and that the vote was narrow like the others - figures circulating in trade coverage have not been independently confirmed, so we do not repeat a margin for it. (This page previously did; the correction follows the vote-results hub, which is the library's source of record on the tallies.)

Two things follow. First, no substance in the room commanded a decisive majority - no vote was carried by more than three, most by two, and at least one member abstained on every question. Second, Emideltide was declined by one vote. A single member voting differently would have produced the opposite outcome on the same evidence.

That does not make the outcome arbitrary, and it does not mean DSIP's evidence base is stronger than we have described - it is thin on its own merits, and would be thin had the vote gone the other way. What the margins do establish is that this was a genuinely contested judgement by a divided panel, not a clear verdict. Treating a one-vote committee outcome as a settled scientific finding about the molecule reads far more into it than the record supports. The evidence is the reason to be cautious about DSIP. The vote is not.

Note on sourcing: these tallies are drawn from trade and regulatory coverage of the meeting rather than from the official minutes. They are consistent across independent sources, but anyone citing an exact count in a formal context should confirm it against the FDA's published meeting record.

October 2026: the interim policy, and why it does not answer the DSIP question

On 14 October 2026 HHS and the FDA submitted a document titled "Interim Access Policy for Compounding Using Certain Peptides" to the Office of Information and Regulatory Affairs at the White House Office of Management and Budget. As of 19 October 2026 it is pending review, has not been issued, and its text is not public. Which substances, routes and conditions it covers is unknown, so nobody can yet say whether DSIP is covered. Press coverage has linked the policy to the peptides the committee recommended in July, such as BPC-157; DSIP is the one the committee voted against, and nothing published suggests that has been revisited. Law firms expect, if issued, a temporary enforcement-discretion posture for 503A pharmacies, which would approve nothing and add nothing to the 503A Bulks List. Any claim before the text appears that DSIP is "now allowed" is a guess.

What DSIP was supposed to do for sleep architecture

The theory is appealing, which is exactly why it sells. DSIP was proposed to promote slow-wave (deep) sleep - the delta-dominant stage that concentrates in the first part of the night and that governs physical recovery and the nocturnal growth-hormone pulse (the mechanism we cover in how peptides affect deep sleep). A peptide that reliably deepened slow-wave sleep would be genuinely valuable.

But there is a general gap here worth naming, because it recurs across this whole category: a compound that acts on sleep architecture is not thereby a treatment for a sleep complaint. Those are different claims. Architecture is a measurement - what a hypnogram shows about the distribution of stages across a night. A sleep complaint is an experience: not falling asleep, not staying asleep, not feeling restored. A molecule can plausibly shift the first without touching the second, and the history of sleep pharmacology is substantially a history of that gap. In DSIP's case the evidence never even caught up to the premise: the deep-sleep effect that gave it its name has not translated into consistent, well-controlled human results. It's a suggestive molecule with a weak evidence base - promising in theory, unproven in practice, as we lay out in peptides for sleep and Epitalon and DSIP for sleep and longevity.

Evidence-grounded alternatives that fared differently

If DSIP is off the table for you, the honest reframe is that the alternatives aren't mostly other peptides - they're the foundations that actually drive sleep.

Epitalon (recommended by the committee). Reviewed the same day, Epitalon was one of the six the committee backed. It's mostly discussed for longevity and melatonin-rhythm claims, with a secondary sleep angle. Worth knowing: a favourable committee vote is a nonbinding statement about compounding eligibility, not an approval and not a validation of its bolder claims - and Epitalon's own human evidence is also limited. It isn't a like-for-like "better DSIP." Treat it as investigational too, and note that its legal status is no different today than DSIP's.

Foundations first. The reframe that matters: most poor sleep isn't a peptide deficiency - it's circadian, behavioural or environmental. Light, consistent timing, a cool dark room, a real wind-down, and cutting the alcohol and late caffeine that specifically shred slow-wave sleep resolve the majority of sleep complaints, and no peptide competes with them. The sleep foundations guide covers the levers in order of impact. And if good foundations still leave you exhausted, the next step is screening for something like sleep apnea - a medical condition - not reaching for a research vial.

What this means if you were considering DSIP

The practical takeaway is straightforward. DSIP is investigational, its human evidence is weak, and the one committee willing to back six other peptides declined to back it. That doesn't make it uniquely dangerous, and it isn't an FDA verdict on the molecule - but it does place it firmly at the far, speculative end of the sleep toolkit, behind the foundations, behind screening for medical causes, and behind honest expectations. If it's considered at all, it belongs in supervised care with verified product, not a website purchase justified by a suggestive name. For the wider regulatory picture, see what 503A compounding actually is.

Frequently asked questions

What is emideltide? Emideltide is the docket name for delta sleep-inducing peptide (DSIP), a nonapeptide first described decades ago in animal research on slow-wave sleep. It is investigational, is not an FDA-approved medicine, and its human evidence base is limited and dated. It is the substance the FDA's advisory committee declined to recommend for the 503A compounding bulks list on 24 July 2026.

Is emideltide the same as DSIP? Yes - the same substance under two names. "Emideltide" is the regulatory docket name; "DSIP" is the research and marketing name. Any product presented as though they are two different things is misrepresenting what it is.

Did the FDA reject DSIP? Not in the sense the headlines imply. An FDA advisory committee declined to recommend Emideltide (DSIP) for the 503A compounding bulks list on 24 July 2026. That vote is nonbinding, it is not a decision by the FDA itself, and it is not a rejection of the substance. The agency retains sole authority over the list and would have to publish a proposed rule, take public comment and issue a final rule before anything is settled either way.

Can I get emideltide from a compounding pharmacy? No. The July 2026 recommendation was unfavourable, it was nonbinding either way, and no rulemaking has been completed for any of the seven substances considered. Nothing about the substance's availability changed in July.

Is DSIP banned now? No. A negative advisory vote imposes no new prohibition. DSIP's underlying investigational status is unchanged - it simply wasn't advanced.

What's the best-evidenced sleep peptide? Honestly, none has strong human evidence - the sleep peptides as a class are investigational. The best-evidenced sleep interventions aren't peptides at all: light, timing, environment, and limiting alcohol and late caffeine.

Does Epitalon help sleep? Epitalon was among the six recommended in July 2026 and is discussed for melatonin-rhythm support, but its human evidence is also limited and its bolder longevity claims outrun the data. A committee recommendation concerns compounding eligibility, is nonbinding, and is not proven sleep benefit.

Related reading

• Peptides for sleep: DSIP, epithalon and the honest evidence · Epitalon & DSIP for sleep and longevity · How peptides affect deep sleep: the GH pulse · Sleep optimization: the foundations · After the FDA vote: what changed · What 503A compounding is
• Part of The Complete Guide to Sleep Optimization

Want this read at its real weight? Vivre Labs approaches investigational sleep compounds evidence-first: foundations and baseline bloodwork before anything else, verified product, and the evidence limitations stated up front. Book a consult to understand what the evidence really supports - Telegram.

Educational content, not medical advice. DSIP/emideltide and Epitalon are investigational with limited human evidence; a PCAC vote (favourable or unfavourable) is nonbinding and does not change legal access. Any use is physician-directed with verified product; do not self-source peptides. Persistent sleep problems and suspected sleep apnea warrant clinical evaluation. Claims for the Malaysian market are subject to MAB requirements.

References

• FDA Pharmacy Compounding Advisory Committee meeting, 23–24 July 2026, on peptide bulk drug substances for the 503A Bulks List (FDA advisory committee calendar). · 24 July 2026: the committee discussed Emideltide - also referred to as delta sleep-inducing peptide (DSIP) - plus Semax-related and Epitalon-related substances; Semax and Epitalon were recommended, Emideltide was not. It was the only unfavourable vote of the session. Reported vote tallies circulated in trade coverage should be checked against the official meeting minutes before being cited as exact.
• PCAC votes are advisory and nonbinding; they did not make any substance lawful for compounding under Section 503A. FDA retains sole authority over placement on the 503A Bulks List, and the remaining sequence is: FDA docket review → proposed rule → public comment → final rule. Nothing has changed legally as of 13 September 2026.
• DSIP (delta sleep-inducing peptide), docket name Emideltide: named for delta/slow-wave sleep in early animal research; limited, dated, mixed human data; mechanism not firmly established.
• Sleep foundations (light, timing, environment, alcohol/caffeine) remain the best-evidenced interventions for sleep quality.
• Interim policy: HHS/FDA submitted "Interim Access Policy for Compounding Using Certain Peptides" to OIRA/OMB for review on 14 October 2026; pending review, not issued, text not public as of 19 October 2026; covered substances unknown. Emideltide (DSIP) PCAC outcome: declined 6-7 with one abstention, advisory only. Nothing has been added to the 503A Bulks List as of 19 October 2026. Sources: Buchanan Ingersoll & Rooney (16 October 2026) https://www.bipc.com/fda-submits-interim-peptide-compounding-policy-for-white-house-review-what-pharmacies-should-know · Holland & Knight, "Peptides at a Crossroads" (October 2026) https://www.hklaw.com/en/insights/publications/2026/10/peptides-at-a-crossroads-what-wellness-providers-need-to-know
• Regulatory analysis: Buchanan Ingersoll & Rooney, "FDA PCAC Recommends Six Peptides for the 503A Bulks List" and "FDA Voted Yes on Six Peptides - Now What"; Health Affairs Forefront, "FDA Advisory Committee's Vote May Open Drug Compounding Back Door" (2026).